Proton Pump Inhibitors in Renal Disease and Ace-1/ARBS Considered & Nature vs Nurture: Integrative Strategies to Treat Obesity-2018 WOMA Primary Care Update

Proton Pump Inhibitors in Renal Disease and Ace-1/ARBS Considered Mark Baldwin, DO  
Proton Pump Inhibitors (PPIs) and ACE-I/ARBs have become some of the most widely prescribed medications in the past several decades. A number of recent studies have implicated PPIs in a variety of acute and chronic renal conditions and other associated medical conditions. Should ACE-I/ARBs be discontinued in the face of advanced CKD? New research is suggesting this, but what is the cost to benefit? This talk sorts through the data to give a clear recommendation for these medications.
Nature vs Nurture: Integrative Strategies to Treat Obesity Gina Many, PhD  
 The etiology of obesity is complex. Individual variation in BMI is influenced by genomics, but genomics does not explain the surge in obesity rates over the past 30 years. Epigenetic imprinting during critical stages of development substantially impacts the heritability of obesity. Unlike genomics, which is unmodifiable, interventions targeting epigenetic imprinting show promise in obesity prevention. Beyond the imprinting stage of obesity prevention, treatment recommendations for obesity and weight maintenance are reviewed, with emphasis on integrative cognitive and lifestyle approaches.